S
Sarepta Therapeutics Inc (SRPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$15.13
-0.94 (-5.85%)
Market Cap: $1.72B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sarepta Therapeutics Inc (SRPT) Valuation Multiples
Sarepta Therapeutics (SRPT) trades at 0.8x sales and 1.0x book value. Its P/S of 0.8x is below its 5-year median of 7.7x. Its forward P/E is 16.2x.
Current Multiples
Its free cash flow yield is 11.0%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 16.2x |
| Price to sales | 0.8x |
| Price to book | 1.0x |
| Price to FCF | 9.1x |
| EV/FCF | 11.3x |
| PEG | N/A |
| FCF yield | 11.0% |
Historical Medians
Against its 10-year medians, its P/S is 92.7% below 11.0x and its P/B is 88.9% below 9.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.8x | 7.7x | 11.0x |
| P/B | 1.0x | 8.8x | 9.0x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.0x in 2025 to 276.4x in 2016. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $21.52 | N/A | 1.0x | 2.0x |
| 2024 | $121.59 | 33.0x | 6.3x | 8.6x |
| 2023 | $96.43 | N/A | 7.2x | 11.8x |
| 2022 | $129.58 | N/A | 12.2x | 29.6x |
| 2021 | $90.05 | N/A | 10.2x | 7.8x |
| 2020 | $170.49 | N/A | 24.6x | 17.6x |
| 2019 | $129.04 | N/A | 24.9x | 11.7x |
| 2018 | $109.13 | N/A | 24.1x | 7.3x |
| 2017 | $55.64 | N/A | 21.6x | 4.5x |
| 2016 | $27.43 | N/A | 276.4x | 4.4x |
Frequently Asked Questions About SRPT
What is SRPT's forward P/E ratio?
Sarepta Therapeutics has a forward P/E ratio of 16.2x.
What is SRPT's price to sales ratio?
Sarepta Therapeutics has a price to sales ratio of 0.8x.
SRPT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors